Acacia Pharma has a late-stage pipeline of nausea and vomiting product candidates for surgical and cancer patients; large and growing markets with significant unmet medical need.
Post-operative nausea & vomiting (PONV)
PONV is a common complication of surgery, occurring in approximately 30% of surgical patients and up to 80% of high-risk patients.
Chemotherapy induced nausea & vomiting (CINV)
CINV is one of the most common and feared side effects of cancer chemotherapy.
Acacia Pharma’s BAREMSIS® Prevents Post-Operative Nausea & Vomiting In High-Risk Patients (published in Anesthesiology)
FDA Acceptance Of NDA Filing For BAREMSIS® For The Management Of PONV
Positive Results From 4th And Final Pivotal Phase 3 Trial Of BAREMSIS® For Rescue Treatment Of PONV
View all news